triple-negative-breast-cancer

Documents about triple-negative-breast-cancer

• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer#859622ClinicalTrials.gov
• Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)#844744ClinicalTrials.gov
• Reverse Triple Negative Immune Resistant Breast Cancer#325309ClinicalTrials.gov
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer#917821ClinicalTrials.gov
• Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer#387169ClinicalTrials.gov
• MicroRNA Profiles in Triple Negative Breast Cancer#141066ClinicalTrials.gov
• Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer#245507ClinicalTrials.gov
• Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer#853755ClinicalTrials.gov
• VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study#67874ClinicalTrials.gov
• Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy#123570ClinicalTrials.gov
• Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer#810240ClinicalTrials.gov
• Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer#801676ClinicalTrials.gov
• Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy#234433ClinicalTrials.gov
• Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer#852144ClinicalTrials.gov
• Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy#234493ClinicalTrials.gov
• Efficacy of Interleukin-2 in Triple Negative Breast Cancer#307467ClinicalTrials.gov
• Neoadjuvant Goserelin for Triple Negative Breast Cancer#860939ClinicalTrials.gov
• Sitravatinib in Metastatic Breast Cancer#914925ClinicalTrials.gov
• Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer#28435ClinicalTrials.gov
• Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer#876874ClinicalTrials.gov
• Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer#623531ClinicalTrials.gov
• Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer#800417ClinicalTrials.gov
• TNBC Gut Microbiota During Neoadjuvant Treatment#405156ClinicalTrials.gov
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients#838930ClinicalTrials.gov
• Study on Bisphosphonates Targeting Triple-negative Breast Cancer#851034ClinicalTrials.gov
• Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer#910604ClinicalTrials.gov
• QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine#387197ClinicalTrials.gov
• Triple-Negative Breast Cancer Versus Non-Triple-Negative Breast Cancer: The Impact of Pd and Pt Complexes on Basal-Like Triple-Negative Breast Cancer.#170565NCBI PubMed Central
• A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer#353297ClinicalTrials.gov
• Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients#287389ClinicalTrials.gov
• Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1#845678ClinicalTrials.gov
• Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer#300271ClinicalTrials.gov
• PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer#405149ClinicalTrials.gov
• Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer#321549ClinicalTrials.gov
• Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.#900025ClinicalTrials.gov
• Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)#909685ClinicalTrials.gov
• Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer#366591ClinicalTrials.gov
• A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients#1009490ClinicalTrials.gov
• A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies#849810ClinicalTrials.gov
• Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer#867808ClinicalTrials.gov
• A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer#825757ClinicalTrials.gov
• Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer#850596ClinicalTrials.gov
• Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer#873938ClinicalTrials.gov
• Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer#835000ClinicalTrials.gov
• Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer#272340ClinicalTrials.gov
• Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer#848282ClinicalTrials.gov
• Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer#127606ClinicalTrials.gov
• Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer#918519ClinicalTrials.gov
• Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212#827347ClinicalTrials.gov
• Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer#811741ClinicalTrials.gov